----
Current ValuationThe current P/E ratio is -1.38, above the reasonable range, cheaper than 9.96% of the time in the past 1 years, and the industry ranks 227/602, the industry Median -2.07.
-1.38xP/E
$2.56Stock price
$-1.86Earnings per share
-1.38xP/E
Stock price$2.56Earnings per share$-1.86
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -2.49x
- Typical range
- -3.12x–-1.84x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
020406080
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
GILDUSGilead Sciences | -56.20x | 148.77% | $182.09B |
MRNAUSModerna | -24.89x | 15.53% | $78.44B |
CSLLYUSCSL Limited | -23.41x | -- | $60.36B |
NTRAUSNatera | -296.43x | 6.99% | $57.02B |
RVMDUSRevolution Medicines | -24.35x | 62.27% | $43.05B |
ROIVUSRoivant Sciences | -94.27x | 146.49% | $25.10B |
BNTXUSBioNTech SE | -12.22x | 15.84% | $23.93B |
INSMUSInsmed | -25.38x | 74.34% | $22.22B |
SMMTUSSummit Therapeutics | -16.73x | 19.55% | $14.32B |
BBIOUSBridgebio Pharma | -18.79x | 28.48% | $13.00B |
MDGLUSMadrigal Pharma | -34.66x | 51.06% | $11.27B |
IBRXUSImmunityBio | -10.41x | 151.32% | $10.33B |
TWSTUSTwist Bioscience | -74.95x | 25.09% | $10.25B |
PCVXUSVaxcyte | -9.36x | 48.80% | $9.96B |
KYMRUSKymera Therapeutics | -30.07x | 4.94% | $9.01B |
ARWRUSArrowHead Pharma | -27.14x | 36,308.30% | $8.68B |
CYTKUSCytokinetics | -9.50x | 6.37% | $8.50B |
PRAXUSPraxis Precision Medicines | -22.89x | 3.05% | $7.76B |
ABVXUSAbivax SA | -16.29x | 22.49% | $7.59B |
IONSUSIonis Pharma | -12.98x | 50.60% | $7.34B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
